CLINICAL TRIAL: PI &PHARMACOKINETIC SINGLE AGENT STUDY OF DRUG IN PTS W ADV MALI

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 NCI UO1支持的这一第一阶段方案的目标是建立晚期癌症和不同程度肝功能障碍(轻度、中度和重度)患者组中帕佐帕尼的最大耐受量(MTD)和剂量限制毒性(DLT)，以便为此类患者提供帕佐帕尼的适当剂量建议。另一个目标是记录与帕佐帕尼治疗相关的任何抗肿瘤活性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of this Phase I, NCI UO1 supported protocol is to establish the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of pazopanib in groups of patients with advanced cancer and varying degrees of hepatic dysfunction (mild, moderate, and severe) in order to provide appropriate dosing recommendations for pazopanib in such patients. Another goal will be to document any antitumor activity associated with pazopanib treatment.